Form 8-K - Current report:
SEC Accession No. 0001193125-25-147005
Filing Date
2025-06-25
Accepted
2025-06-25 16:35:12
Documents
13
Period of Report
2025-06-23
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d949875d8k.htm   iXBRL 8-K 27434
2 EX-4.1 d949875dex41.htm EX-4.1 8117
  Complete submission text file 0001193125-25-147005.txt   156639

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA annx-20250623.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20250623_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20250623_pre.xml EX-101.PRE 11709
15 EXTRACTED XBRL INSTANCE DOCUMENT d949875d8k_htm.xml XML 3768
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 251074052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)